Overview

A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy

Status:
Recruiting

Trial end date:
2023-04-30

Target enrollment:

Participant gender:

Summary

To assess anti-tumor activity of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression on second or third line treatment (after failure on at least of imatinib and sunitinib) in terms of progression-free survival (PFS)

Phase:

Phase 2

Details

Lead Sponsor:

Maria Sklodowska-Curie Institute - Oncology Center

Treatments:

Antibodies, Monoclonal
Avelumab
Axitinib